相关实验视频
Updated: Jan 16, 2026

09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
3.9K
阿尔茨海默病在河口海豚大脑转录组中的特征
Wendy Noke Durden1, Megan K Stolen1,2, Susanna P Garamszegi3
1Hubbs-SeaWorld Research Institute, Melbourne Beach, FL, USA.
Communications biology
|September 30, 2025
概括
有害的藻类繁殖 (HABs) 释放毒素,这些毒素在海豚大脑中积累,增加了阿尔茨海默病 (AD) 的风险. 在HAB期间季节性暴露于2,4-DAB会提高AD的特征,突出显示神经健康的风险.
科学领域:
- 神经科学是一个神经科学.
- 环境毒理学环境毒理学
- 海洋哺乳动物健康
背景情况:
- 气候变暖加剧了有害的藻类繁殖 (HAB),对海洋生态系统构成风险.
- 了解HAB相关毒素对神经系统的影响对于公共卫生至关重要.
- 佛罗里达州印第安河湖中的海豚经历季节性HAB.
研究的目的:
- 为了研究HAB暴露对浅海豚大脑转录组的影响.
- 量化不同季节海豚大脑中2,4-氨酸 (2,4-DAB) 的度.
- 为了确定与HAB暴露相关的分子途径和神经病理变化.
主要方法:
- 来自佛罗里达州浅动物的海豚脑组织的分析.
- 2,4-氨酸 (2,4-DAB) 神经毒素水平的量化.
- 转录组分析以确定差异表达的基因.
- 评估神经病理变化和阿尔茨海默病 (AD) 标志物.
主要成果:
- 在 HAB 季节,海豚大脑中的 2,4-DAB 度是海豚大脑的 2900 倍.
- 鉴定了536个差异表达的基因,表明GABAergic突触受损和底层膜变化.
- 随着季节性2,4-DAB暴露,观察到AD风险因素增加和AD类的神经病理变化.
- 增加AD基因表达与2,4-DAB水平相关.
结论:
- 季节性暴露于来自HAB的2,4-DAB显著增加了海豚大脑中阿尔茨海默病 (AD) 的特征.
- 由于气候变暖,HAB对海洋哺乳动物的神经健康构成越来越大的威胁.
- 这项研究提供了对与环境毒素有关的神经退行性疾病风险人口的见解.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824

